Navigation Links
InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
Date:5/28/2009

LOS ALTOS, Calif., May 28 /PRNewswire/ -- InteKrin Therapeutics, Inc. announced today it will present Phase 2a clinical data for INT131, a Selective PPAR Modulator (SPPARM), at the American Diabetes Association annual meeting in New Orleans Saturday, June 6, 2009 during the "Novel Diabetes Therapies in Development in Humans" session at 4:00 pm CDT.

Dr. Alex DePaoli, Chief Medical Officer of InteKrin Therapeutics, will provide a summary of the latest clinical data supporting the design of INT131 to safely and effectively address insulin resistance in a presentation entitled "INT131: Significantly Lowers Glucose Without Typical Thiazolidinedione (TZD) Side Effects in Patients with Type 2 Diabetes."

About INT131

INT131 is a next-generation insulin sensitizer currently in Phase 2b testing that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Purposefully designed as a SPPARM, INT131 selectively modulates PPAR-gamma, thereby allowing the retention of the clinically proven anti-diabetic efficacy of PPAR gamma activation, while mitigating or eliminating the well recognized side effects of TZD full PPAR gamma agonists rosiglitazone and pioglitazone (Avandia(R) and Actos(R) respectively).

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and me
'/>"/>

SOURCE InteKrin Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
2. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
3. Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
4. Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
5. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
6. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
7. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
8. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
9. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
10. Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
11. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... VIEW, Calif. , July 22, 2014 /PRNewswire/ ... resonance imaging (MRI) market, Frost & Sullivan recognizes ... for Product Leadership. Siemens Healthcare,s FREEZEit solution, which ... the need for robust and motion-insensitive imaging. The ... boosted the evolution of body MRI imaging in ...
(Date:7/22/2014)... Ariz. , July 22, 2014  A ... of a SynCardia temporary Total Artificial ... Rochester,s Strong Memorial Hospital with the Freedom® portable ... Fontana, a 64-year-old retiree from a ... decades. He managed the condition with medications, an ...
(Date:7/22/2014)... 2014  PuraMed BioScience®, Inc., (OTCBB: PMBS), a ... and healthcare products, announced today that the company ... "We are pleased to sponsor Operation ... and Chairman of PuraMed BioScience. "Research shows that ... experience migraines much more frequently than the general ...
Breaking Medicine Technology:Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 2Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 3Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 4'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 2'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 3PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 2PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 3
... trial -SOUTH SAN FRANCISCO, Calif., March 30 Hyperion ... II study of HPN-100 for the treatment of urea ... 27th at the 16th Annual Clinical Genetics Meeting of ... M.D., Ph.D., Howard Hughes Medical Institute Investigator and Professor ...
... studied in combination with the most commonly used doses ... in patients with mixed dyslipidemiaORLANDO, Fla., March 29 ... ,s TRILIPIX(R) (fenofibric acid) delayed-release capsules in combination with ... TRILIPIX 135 mg in combination with rosuvastatin calcium ...
Cached Medicine Technology:Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 2Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 3Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 4New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 2New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 3New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 4New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 5
(Date:7/22/2014)... 22, 2014 CyraCom has been ranked ... in the translation and interpreting industry. Released June 2014 ... report titled "The Language Services Market: 2014," also ranked ... world, moving up two spots from 2013. , In ... LSPs that provide interpretation services – a subset of ...
(Date:7/22/2014)... The Muscular Dystrophy Association (MDA) and Jiffy Lube today ... campaign that will raise funds to help save and ... muscle disease. , As part of the campaign, ... centers through Sept. 1, 2014 to make a donation to ... the fight for muscle health. Since 2012, Jiffy Lube has ...
(Date:7/22/2014)... Paul, Minn. (PRWEB) July 22, 2014 ... dental comfort technology, the Restful Jaw ®. The ... the patient’s jaw while minimizing jaw pain, fatigue and ... can experience shorter treatment times when patients do not ... pain. , The Restful Jaw is a vital ...
(Date:7/22/2014)... HealthDay Reporter MONDAY, July 21, 2014 (HealthDay ... asthma appears to offer relief to people with chronic hives ... The prescription drug -- omalizumab (Xolair) -- is already ... approval earlier this year for that use. The current ... dose for a six-month period it seems to be both ...
(Date:7/22/2014)... at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute ... one of the most complex and difficult-to-treat forms ... , Locally advanced pancreatic cancer has the lowest ... cumulative five-year survival rate of only 4 percent ... an option for patients because tumors often involve ...
Breaking Medicine News(10 mins):Health News:CyraCom Ranked Among the World’s Largest Language Service Providers 2Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 2Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 3Health News:Introducing the Restful Jaw – The Only Device Designed to Protect the Patient’s Jaw 2Health News:Introducing the Restful Jaw – The Only Device Designed to Protect the Patient’s Jaw 3Health News:Asthma Drug May Help Those With Chronic Hives 2Health News:Asthma Drug May Help Those With Chronic Hives 3Health News:Unique study focuses on combined treatment approach for locally advanced pancreatic cancer 2Health News:Unique study focuses on combined treatment approach for locally advanced pancreatic cancer 3
... Health Plans Offer Broader ChoiceEAGAN, Minn., April 13 ... today announced the largest array of individual health plan ... buy health insurance on their own. The new plans ... series of "design your own health plan" sessions, in ...
... 13 The American Heart Association, with support from ... three research centers to study the development and mechanisms ... next four year, the centers will be conducting studies ... help improve outcomes for heart attack and heart failure ...
... 5,000 years ago , , MONDAY, April 13 (HealthDay News) -- ... stomach,s sake," may have been heeded more than 5,000 years ... residues found in wine jars left in the tomb of ... had been steeped in herbs including balm, coriander, mint and ...
... Jean Nordin Evans, DDS, FIND and Dr. Robert Evans, DMD, FIND, FAGD ... new medical center located at Mill Run Plaza. , ... Groton, MA ... visionary, announced today that Groton Wellness Medical Center has opened its doors ...
... beyond mere placebo effect , , MONDAY, April 13 (HealthDay ... a 25 percent less nausea during radiation treatments, a new ... Journal of Pain and Symptom Management , also discounted ... as a placebo than an actual pain reliever. , ...
... 13 The Advertising Council, in partnership,with Autism Speaks, ... public,service advertisements (PSAs) featuring professional golfer Ernie Els, and ... about autism and to urge,parents to learn the early ... in every 150 children. , , ...
Cached Medicine News:Health News:Blue Cross Launches Largest Selection of Individual Plans Available in Minnesota 2Health News:Blue Cross Launches Largest Selection of Individual Plans Available in Minnesota 3Health News:Three Medical Centers Awarded Funds to Study Generation of Cardiac Muscle Cells 2Health News:Pharoah's Wine Jar Yields Medicinal Secrets 2Health News:Pharoah's Wine Jar Yields Medicinal Secrets 3Health News:Top Medical and Dental Team Opens Groton Wellness Medical Center in Groton, MA 2Health News:Top Medical and Dental Team Opens Groton Wellness Medical Center in Groton, MA 3Health News:Top Medical and Dental Team Opens Groton Wellness Medical Center in Groton, MA 4Health News:Wristbands May Lessen Nausea After Radiation 2Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 2Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 3Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 4
Tennant angled tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm....
Catalano angled tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Catalano straight tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Kelman - McPherson angled tying forceps is long with tying platform 10 mm, serrated handle and polished finish....
Medicine Products: